A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
enVVeno Medical Corp
NVNO
$3M
Mkt Cap
$10.39
+2.77%
enVVeno Medical Corp (NVNO) has a 5-year average return on invested capital (ROIC) of -30.4%. This is below average and may indicate limited pricing power.
enVVeno Medical Corp (NVNO) has a market capitalization of $210M. It is classified as a small-cap stock.
enVVeno Medical Corp (NVNO) does not currently pay a regular dividend.
enVVeno Medical Corp (NVNO) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
enVVeno Medical Corp (NVNO) generated $-12 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
enVVeno Medical Corp (NVNO) has a debt-to-equity ratio of 0.06. This indicates a conservatively financed balance sheet.
enVVeno Medical Corp (NVNO) reported earnings per share (EPS) of $-66.50 in its most recent fiscal year.
ITEM 1. Business enVVeno Medical Corporation is a late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. Chronic Venous Disease (CVD) is the world’s most prevalent chronic disease, impacting approximately 70% of the adult population of the U.S. Chronic Venous Insufficiency (CVI), is a large subset of CVD, which most often occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe CVI of the deep venous system of the leg.
| Metric | TTM | FY2021 |
|---|---|---|
| Revenue | 0 | - |
| Net Income | -28M | -17M |
| EPS | $-50.05 | $-66.50 |
| Free Cash Flow | -22M | -12M |
| ROIC | -72.7% | -30.4% |
| Gross Margin | - | - |
| Debt/Equity | 0.00 | 0.06 |
| Dividends/Share | $0.00 | - |
| Operating Income | -30M | -17M |
| Operating Margin | 0.0% | - |
| ROE | -93.8% | -53.7% |
| Shares Outstanding | 20M | 0M |
| Metric | ||
|---|---|---|
| Income Statement | ||
| Revenue | N/A | 0 |
| Gross Margin | N/A | N/A |
| R&D | N/A | N/A |
| SG&A | N/A | N/A |
| EBIT | -17M | -30M |
| Op. Margin | N/A | 0.0% |
| Net Income | -17M | -28M |
| Net Margin | N/A | 0.0% |
| Non-Recurring | 0 | 0 |
| Returns on Capital | ||
| ROIC | -30.4% | -72.7% |
| ROE | -53.7% | -93.8% |
| ROA | -48.4% | -85.3% |
| Cash Flow | ||
| Op. Cash Flow | -12M | -22M |
| Free Cash Flow | -12M | -22M |
| Owner Earnings | -18M | -28M |
| CapEx | 368K | 0 |
| Maint. CapEx | 149K | 149K |
| Growth CapEx | 219K | 0 |
| D&A | 149K | 149K |
| CapEx/OCF | N/A | 0.0% |
| Capital Allocation | ||
| Dividends Paid | 0 | 0 |
| Dividend Yield | N/A | N/A |
| Share Buybacks | 0 | 0 |
| Buyback Yield | N/A | 0.0% |
| Stock-Based Comp | 6.0M | 6.0M |
| Debt Repayment | 0 | 0 |
| Balance Sheet | ||
| Net Debt | N/A | -31M |
| Cash & Equiv. | N/A | 31M |
| Long-Term Debt | N/A | N/A |
| Debt/Equity | 0.06 | 0.00 |
| Interest Coverage | -54.0 | -54.0 |
| Equity | 54M | 29M |
| Total Assets | 58M | 32M |
| Total Liabilities | 3.3M | 2.9M |
| Intangibles | N/A | N/A |
| Retained Earnings | -82M | -82M |
| Working Capital | 53M | 53M |
| Current Assets | 55M | 55M |
| Current Liabilities | 1.6M | 1.6M |
| Per Share Data | ||
| EPS | -66.50 | -50.05 |
| Owner EPS | -72.40 | -1.37 |
| Book Value | 218.90 | 1.46 |
| Cash Flow/Share | -47.66 | -1.36 |
| Dividends/Share | N/A | 0.00 |
| Shares Out. | 0.2M | 20.2M |
| Valuation | ||
| P/E Ratio | N/A | -0.2 |
| P/FCF | N/A | N/A |
| EV/EBIT | N/A | N/A |
| Price/Book | 1.0 | 7.1 |
| Price/Sales | N/A | N/A |
| FCF Yield | -21.5% | -10.2% |
| Market Cap | 57M | 210M |
| Avg. Price | 259.14 | 10.39 |
| Year-End Price | 228.55 | 10.39 |
enVVeno Medical Corp passes 0 of 9 quality checks, indicating weak fundamentals.
enVVeno Medical Corp (NVNO) has a return on equity (ROE) of -53.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 1 years of financial data for enVVeno Medical Corp (NVNO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
enVVeno Medical Corp (NVNO) has a book value per share of $218.90, based on its most recent annual SEC filing.
No recent press releases.